All In Biotech

Drug Trial Radar · NCT06853444

A Phase 1/2 Study of ESG206 in Patients With Primary Immune Thrombocytopenia

A Phase 1/2 Study on the Safety, Tolerability, Pharmacokinetics, Pharmacodynamics, Immunogenicity, and Preliminary Efficacy of the Anti-BAFF-R Monoclonal Antibody, ESG206, in Patients With Primary Immune Thrombocytopenia (ITP)

Last checked: Nov 19, 2026Latest source record: May 16, 2025 (this record)Source: ClinicalTrials.govMethods & limitations

Recruiting

Status

Recruiting

Enrollment

84

Planned (sponsor's estimate)

Start

May 8, 2025

Primary completion

Mar 31, 2026

Study completion Apr 30, 2027

Sponsor

Sponsor type
Industry
First posted
Mar 3, 2025

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 1 / Phase 2
Allocation
Non randomized
Model
Single group
Masking
None
Primary purpose
Treatment
FDA-regulated drug
No
Who can join
All sexes, from 18 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

This is a multicenter, open-label Phase1/2 study aimed at evaluating the safety, tolerability, pharmacokinetic (PK) profile, pharmacodynamics (PD), immunogenicity, and preliminary efficacy of ESG206. The study will be conducted in patients with primary immune thrombocytopenia.

Conditions

  • Immune Thrombocytopenia (ITP)

Interventions

  • ESG206Drug

    Administered via intravenous (IV) infusion

  • ESG206Drug

    Administered via intravenous (IV) infusion

  • ESG206Drug

    Administered via intravenous (IV) infusion

  • ESG206Drug

    Administered via intravenous (IV) infusion

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Percentage of Participants Experiencing Any Treatment Emergent Adverse Events and Serious Treatment Emergent Adverse EventsTime frame: Up to 24 weeks.
  2. Confirmed response rateTime frame: Between Week 1 Day 1 and Week 25 Day 1

Locations

1 site in 1 country. Site status is shown where the registry gives one.

  • Qilu Hospital of Shandong University

    Jinan, Shandong, China · Recruiting

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.